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Background: Adverse drug reactions increase morbidity and mortality, and potential drug interactions
(DIs) increase the probability of adverse drug reactions.
Objectives: To survey the potential DIs of dermatologic outpatient prescriptions from the National Health
Insurance Research Database of Taiwan.
Methods: All prescriptions written by dermatologists in 2000 were analyzed to identify potential DIs
among drugs appearing on the same prescription sheet.
Results: Of 150.6 million prescription sheets with 669.5 million prescriptions registered in the National
Health Insurance Research Database of Taiwan, we identiﬁed 6.6 million (4.4%) dermatology prescription
sheets with 19 million (2.8%) prescriptions. The ﬁndings of the study showed that 283,458 potential DIs
were found in this category, accounting for 1.49% per prescription. The most common signiﬁcance Level 1
interaction (1.1%) was between the less-sedative antihistamines (terfenadine/astemizole) and azole
antifungal agents. Among the category of severity, the most common was terfenadine interacting with
cimetidine and ketoconazole (4.4%), followed by astemizole interacting with cimetidine and ketoconazole
(2.9%). The most common drug class interaction occurred between corticosteroids and antacids (48.5%).
Overall, DI incidence in dermatologic patients was lower than that of the general patient population.
Conclusions: Based on the study ﬁndings, we concluded that dermatologists need to be reminded of
having possible potential DIs when prescribing medications. Introducing information technology into the
computerized physician order entry system into the daily practice may reduce potential DIs.
Copyright  2011, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Drug interactions (DIs) may cause treatment failure or side effects,
and subsequent adverse drug reactions (ADRs) may cause consid-
erable mortality and morbidity. From a meta-analysis of prospec-
tive studies in the United States, fatal ADRs are ranked as the fourth
to sixth leading causes of death in hospitalized patients.1 Further-
more, deaths due to medical errors are found to exceed the number
attributable to the eighth leading cause of death in the United
States.2 In a study from the National Health Service in the Unitedgy, Taipei Medical University,
Taiwan.
iwanese Dermatological AssociatioKingdom, 400 patients died or were seriously injured in adverse
events involving medical devices. The National Health Service
study also indicates nearly 10,000 people were reported to have
experienced serious ADR.3 An estimated 5e6.5% of inpatients have
ADR1,4 and 2.5e4.4% of them originally have DIs.5
The mean length of hospital stay and costs of hospitalization are
increased signiﬁcantly in patients with ADRs compared with those
without.6 During hospitalization, drug complications are the most
common ADR type, accounting for 19% of cases.7 Although 70.5% of
patients with ADR become disabled for less than 6 months, 2.6%
developed permanent disabilities and 13.6% led to death.8
An estimated 1.46e35% outpatients may develop ADRs and 13%
of them may have serious drug reactions.9,10 The ﬁnding of a DI
study on a sample database from the National Health Insurancen. Published by Elsevier Taiwan LLC. All rights reserved.
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30%. Among the potential DI pairs, 42,193 (9.9%) pairs were clas-
siﬁed as Level 1 clinical signiﬁcance, representing 3% of all
prescriptions. The ﬁve most common potential DI pairs in the
clinically signiﬁcant Level 1 category are digoxin/furosemide,
digoxin/trichlormethiazide, isoniazid/rifampin, digoxin/amiodar-
one, and warfarin/aspirin.1
Not every health care provider can distinguish potential DIs
from ADRs and take corrective measures accordingly. In a survey
study, Glassman et al11 found that only 44% (ranging from 11% to
64%) clinicians have correctly identiﬁed all drug-drug pairs. The
clinician’s understanding of DI can help decrease ADR, safeguard
patient safety, and avoid associated medicolegal problems.
Medications often cause cutaneous reactions,12 although the
severe forms of drug eruption are rare and account for less than 5%
observed in hospitalized patients.13 Andersen and Feingold14
reviewed the mechanism of adverse DIs’ action of risky drugs
such asmethotrexate, cyclosporine A, antifungal agents, antibiotics,
retinoids, and antihistamines. As many new drugs enter or exit the
market, Barranco15e17 has updated a biennial list of clinically
signiﬁcant DIs in dermatology and offered strategies to identify
potential DIs. However, the epidemiologic investigation for the DI
prevalence rate is still lacking. In a study of potential DIs in
outpatient prescriptions based on a large-scale database, the
French team reported that two dermatologic prescription pairs
with potential DIs (cisapride/imidazole antifungals and retinoids/
tetracyclines) can increase risks of ventricular arrhythmia and
intracranial hypertension, respectively.5 Learning DI proﬁles
is necessary to avoid subsequent ADRs when prescribing
medications.
In this study, we surveyed the quantities and related informa-
tion of prescriptions with potential DIs in dermatologic outpatient
prescriptions for 1-year period.Table 1 Signiﬁcance rating scale of potential drug interactions.21,23
Signiﬁcance Severitya Documentationb
1 Major Established, probable, or suspected
2 Moderate Established, probable, or suspected
3 Minor Established, probable, or suspected
4 Major/moderate Possible
5 Minor Possible
Any UnlikelyMethods
We analyzed dermatologic prescriptions in Taiwan from January 1
to December 31, 2000 to identify potential DIs among drugs on the
same prescription sheet.
Implemented in 1995, the NHI program is a compulsory NHI
system that covers almost the whole population of Taiwan.18 The
NHI claims of computerized information for all outpatient
prescriptions written by all physicians (general practitioners,
specialists, dentists, and traditional Chinese physicians) are kept in
the National Health Insurance Research Database and are released
to researchers for epidemiological studies.19,20
The Bureau of National Health Insurance maintains a large-scale
database of all organizations, physicians, insured clients, proce-
dures, medications, prescriptions, and costs of both inpatient and
outpatient treatments. A monthly updated NHI drug formulary
forms the basis of reimbursement for hospitals and clinics, and
more than 21,000 pharmaceutical references have been validated
by the Bureau of Pharmaceutical Affairs of the Department of
Health. Because of the redundancy of the pharmaceutical refer-
ences, the lists of drug have been reclassiﬁed by the same formu-
lation regardless the type of preparations. The revised drug
formulary has 1600 pharmaceutical formulations. A DI database
was developed inwhich potential DIs were deﬁned according to the
drug pairs in the Drug Interaction Facts, 2001 ed.21 The signiﬁcance1 Lin MS, Chang NC, Yang KYH, Chen YH. The potential drug-drug interactions in
an ambulatory prescription data in Taiwan. The 20th International Conference on
Pharmacoepidemiology and Therapeutic Risk Management. Bordeaux, France, 2004:
36.rating was made up by the summary of onset, severity, and docu-
mentation of each DI. By this deﬁnition, the level of signiﬁcance for
a DI is rated from a scale of 1e5. A rating of 1 is major in severity
with the effects of potentially life-threatening and with certain
documented evidences, whereas a rating of 5 is unlikely evidenced
or only limited data in resulting minor severity.22 Of 9328 DI pairs,
1048 pairs are classiﬁed as signiﬁcance Level 1 and 3347 pairs Level
2 (Table 1).
Health care facilities in Taiwan are classiﬁed into four typesd
medical centers, regional hospitals, local hospitals, and private
practice clinics. They are deﬁned by the scales, number of beds, and
quality of medical and nursing care. The categorizing task is
managed by the Taiwan Joint Commission of Hospital Accredita-
tion, a quasi-ofﬁcial body supported by the Department of Health of
Executive Yuan of Taiwan. The rate of reimbursements differs
because of the different type of organizations that could provide
ﬁnancial support to the hospitals.
We analyzed and identiﬁed the prescription drugs with poten-
tial DIs among drugs that appeared on the same prescription sheet
by cross-checking with the revised drug list and potential DI
database using Structured Query Language procedures under
MySQL v4.018 database server platform (Sun Microsystems, Santa
Clara, CA, USA). We excluded interactions that involved two or
more different dosages or frequencies of the same drug.
The NHI prescriptions written by all dermatologists from
January 1 to December 31, 2000 were analyzed. The identiﬁable
patient data were censored to insure patient conﬁdentiality. The
following relevant data were extracted from each prescription
sheet including patient ID, date of birth, clinic ID, facility type,
prescribing physician ID, number of drugs, generic pharmaceutical
ingredients regardless of the formulations (i.e. systemic or topical),
diagnosis (in International Classiﬁcation of Disease, Ninth Revision,
Clinical Modiﬁcation codes), and dispensing pharmacist ID. From
those data, we also generated the following attributes such as DI
pair, signiﬁcance rating, severity level, documentation level, and DI
effects.
We performed descriptive statistical analysis using SAS 8.02
(Institute Inc., Cary, NC, USA).
Results
In 2000, we identiﬁed 150,560,023 prescription sheets with
669,449,835 prescriptions administered to the Bureau of National
Health Insurance. We identiﬁed 6,651,820 (4.4%) dermatologic
prescription sheets with 19,047,309 (2.8%) prescriptions in
4,947,346 patients. The mean number of drugs per sheet was
2.84 0.04.
We found 283,458 prescriptions with potential DIs, represent-
ing 1.49% per prescription and 4.26% per sheet. Most DIs are clini-
cally irrelevant and negligible with signiﬁcant interactions onlya Severity: Major: life-threatening or permanent damage; Moderate: deteriora-
tion of patient’s status; Minor: bothersome or little effect.
b Documented literature: Established: proven to occur in well-controlled studies;
Probable: very likely, but not proven clinically; Suspected: may occur, some good
data, needs more study; Possible: could occur, but data are very limited; Unlikely:
doubtful, no good evidence of an altered clinical effect.
Table 3 Drug interaction proﬁles.
Signiﬁcance Onseta Severity Documentation n %
1 Rapid Major Established 13 1.44
Probable 50
Delayed Major Established 419
Probable 3209
Possible 399
2 Rapid Moderate Established 120 29.85
Probable 894
Suspected 293
Delayed Moderate Established 205
Probable 47,615
Suspected 35,474
3 Rapid Minor Probable 1056 1.14
Suspected 609
Delayed Minor Probable 1500
Suspected 63
4 Rapid Major Possible 66 6.47
Moderate Possible 72
Delayed Major Possible 17,656
Moderate Possible 555
Y.-J. Chang et al. / Dermatologica Sinica 29 (2011) 81e85 83accounting for 1.44%. The most frequent DIs and percentage of
signiﬁcance levels are summarized in Tables 2 and 3, respectively.
Among signiﬁcance Level 1 DIs, the interactions between
less-sedative antihistamines (terfenadine and astemizole) and
azole antifungal agents were the most common (1.1%). As shown
in Table 4, this combination increased potential risk of car-
diotoxicity. As for interactions of major severity, terfenadine’s
interactions with cimetidine and ketoconazole were ranked ﬁrst
(4.4%), followed by astemizole’s interactions with cimetidine and
ketoconazole (2.9%). Those interactions would also result in
potential risk of increased cardiotoxicity (Table 5). The most
commonly involved pairs of drug type in DIs were interactions
of corticosteroids and antacids (48.5%) with signiﬁcance Level 5
(Table 6).24
Among the relationship of DIs and organization types, we found
more DIs occurred in private practice with prevalence of 1.60%. DI
incidence in this study was higher in the regional hospital group,
followed by the local hospital group (Figure 1). The prevalence of
DIs decreased after 40 age of years peaking at the fourth decade
(1.63%).5 Rapid Moderate Unlikely 7 61.10
Minor Possible 5806
Unlikely 14
Delayed Moderate Unlikely 12,781
Minor Possible 153,498
Unlikely 1084
Total 283,458 100
a Onset of drug interactions: Rapid: within 24 hours; Delayed: days to weeks.Discussion
The patient safety issues were brought to attention in a report “To
Err is Human”, published by the Institute of Medicine.2 The prob-
lems of ADRs, especially DIs, have also been reviewed in general
medicine but not much in dermatological ﬁeld in recent years.
Dermatologists are increasingly faced with complex problems of
drug eruptions due to the high prevalence of polypharmacy in their
daily practice. Unlike ADRs that are often unpredictable, DIs can be
avoided if physicians take extra precautions in prescribing. The data
in this study are thought to be the ﬁrst large-scale investigation of
potential DIs of dermatologic outpatient prescriptions in a nation-
wide population involving 4.9 million patients and 19 million
prescriptions. The result of this study showed that 4.26% of these
prescriptions will develop potential DIs, an estimate of one DI in
every 17 patients. This incidence rate of DI occurring in dermato-
logic outpatient prescriptions was lower compared with the
general population.
The interactions of gastrointestinal medications (antacids and
histamine-2 antagonists) account for nearly two-third of total DIs.
The most common DI involved interactions with aluminum
hydroxide and account for over half of the all interactions (54.2%),
and followed by the interactions of cimetidine. With regards to
drug class, the top interaction pair was antacid and corticosteroids
(48.5%), systemically or topically administered. This could reﬂect
the high prevalence of prescribing such combination in Taiwan,
although the signiﬁcance level is 5 and the interaction results in
mild decrease in the pharmacologic effect of corticosteroids.21
Interestingly, there were 8724 (3.1%) interactions of aluminumTable 2 Top 10 drug interactions for the general population.
Drug A Drug B Signiﬁcance n % Overall %a
Betamethasone Aluminum hydroxide 5 67,858 23.94 0.30
Dexamethasone Aluminum hydroxide 5 43,729 15.43 0.19
Triamcinolone Aluminum hydroxide 5 11,362 4.01 0.05
Minocycline Aluminum hydroxide 2 11,299 3.99 0.05
Doxycycline Aluminum hydroxide 2 10,900 3.85 0.05
Terfenadine Cimetidine 4 10,578 3.73 0.05
Doxycycline Cimetidine 5 10,129 3.57 0.04
Ketoconazole Cimetidine 2 8929 3.15 0.04
Minocycline Phosphate 2 8873 3.13 0.04
Cimetidine Aluminum hydroxide 5 8724 3.08 0.04
a Total potential drug interactions: 22,812,747.hydroxide and cimetidine, which are always used for peptic ulcer
medications, that rank 11th in DI pairs (not shown) that cimetidine
might be considered as an antihistamine.
The concurrent administration of antibiotics and metal ions,
such as calcium, aluminum, zinc, or bismuth, may result in clini-
cally signiﬁcant impairment of gastrointestinal absorption and
therefore reduce the anti-infective response.14,15,21,25 Tetracyclines
and quinolones are examples of the oral antibiotics that interact
with metal ion contained in antacids. In this study, the combined
use of aluminum antacid and doxycycline/minocycline occurred in
22,199 (7.8%) prescriptions that might develop potential DI. Opti-
mally separating the ingestion times between the antibiotics and
metal ion may reduce the extent of interaction.
Drugs that affect hepatic metabolism might interact with anti-
biotics. The interactions occur because of modiﬁcation of hepatic
metabolism related to either enzyme inhibition or enzyme induc-
tion. Enzyme inhibition occurs when metabolism of one drug is
inhibited by another drug that is being administered concurrently.
In contrast, enzyme induction occurs when the metabolism of one
drug is increased by another drug that is being administered. The
enzymes most commonly affected are components of the cyto-
chrome P450 (CYP 450) metabolic enzyme system, and CYP3A4 isTable 4 Signiﬁcance Level 1 drug interactions.
Drug A Drug B n %
Terfenadine Ketoconazole 1879 0.66
Astemizole Ketoconazole 1188 0.42
Oxacillin Tetracycline 175 0.06
Dexamethasone Rifampin 174 0.06
Betamethasone Rifampin 132 0.05
Ampicillin Doxycycline 83 0.03
Terfenadine Erythromycin 75 0.03
Oxacillin Doxycycline 73 0.03
Gentamicin Furosemide 48 0.02
Triamcinolone Rifampin 42 0.01
Figure 1 Relationship of prescriptions, drug interactions, and facility type.
Table 5 Top ﬁve drug interactions of major severity.
Drug A Drug B Signiﬁcance n %
Terfenadine Cimetidine 4 10,578 3.7
Astemizole Cimetidine 4 6998 2.5
Terfenadine Ketoconazole 5 1879 0.7
Astemizole Ketoconazole 5 1188 0.4
Oxacillin Tetracycline 1 175 0.1
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inhibition and induction of drug metabolism.14,15,25 Macrolides and
rifamycin antibiotics frequently develop such interactions.15 Inter-
actions between corticosteroids and rifampin, a rifamycin antibi-
otic, occurred in 348 prescriptions that account only 0.12% of DIs in
dermatology, whichmay have resulted in decreased pharmacologic
and toxic effect of corticosteroid.21
Few potentially life-threatening risks were encountered among
all DIs from this study. The results showed that interactions of
second-generation antihistamines such as terfenadine and aste-
mizole were ranked ﬁrst (7.3%), which can potentially cause QT
prolongation in electrocardiography and/or cardiotoxic risk.
Fortunately, those drugs are seldom used now and there are more
safe nonsedative antihistamines available. Although patients with
skin problems are generally considered to have a minor illness, the
results of this study showed that in 1 year more than 3000
dermatologic patients in Taiwan were exposed to the risk of
arrhythmia through their dermatologic medications. The ﬁndings
of our study show that interactions of azole antifungal agents
(ketoconazole/itraconazole) and other drugs had 1.09% of all
dermatologic DIs. Sixteen drugs have been frequently referred as
“red ﬂag” drugs in drug metabolism and DIs17. They have been
found to account for 56 of the 70 clinically signiﬁcant DIs (80%) in
Barranco’s17 most recent study. Of 16 drugs, just 3 red ﬂag drug
families (azole antifungal agents, macrolide antibiotics, and sero-
tonin reuptake inhibitors) have accounted for 41 of the total 70 DIs
(58%).17 The result of our study shows similar ﬁnding and lends
support to Barranco’s study.15,17 In our study, 46 (0.02%) interac-
tions with methotrexate were found, including nonsteroidal anti-
inﬂammatory drugs and sulfonamides that might induce
increased methotrexate toxicity or bone marrow suppression,
respectively,21 but no interactions of azathioprine, cyclosporine,
and retinoids that always being concerned were found. Based on
our ﬁndings, we suggest that dermatologic patients may expect
higher safety standards to cope with their diseases.
Evidence shows that computerized DI screening systems reduce
DIs and adverse drug events (ADEs).11,26,27 It has been suggested
that the electronic medical record and computerized physician
order entry systems that alert the clinicians contributed to the
decreased incidence of potential DIs and related ADEs.28 These
computerized medication alert systems are implemented more
widely inmedical centers than in other type of health care facilities.
It is further speculated that such safety mechanism is the reasonTable 6 Top 10 drug interactions by drug class.
Drug Class A Drug Class B Signiﬁcance n %
Corticosteroids Antacids 5 137,596 48.54
Tetracyclines Cimetidine 5 12,776 4.51
H-2 antagonists Antacids 5 10,289 3.63
Indomethacin Antacids 5 4042 1.43
Mefenamic acid Magnesium salts 5 2561 0.90
Benzodiazepines Antacids 5 2395 0.84
Acetaminophen Anticholinergics 5 1610 0.57
Cimetidine Anticholinergics 5 665 0.23
Phenothiazines Aluminum salts 5 650 0.23
H-2¼ histamine-2.why medical centers have lower DI incidence than that of other
health care facilities.
With the developments in genetic engineering and biotech-
nology within the past 10 years, there are multiple bioengineered
agents being used to treat immune-mediated disorders such as
rheumatoid arthritis, psoriasis and psoriatic arthritis, ankylosing
spondylitis, and pemphigus. The application of such biologic agents
is increasing, and the potential interaction with other therapeutic
modalities is another important issue that clinicians will wrestle
with not only because of long-term use of such agents but also the
patients may lie about their immunocompromised status. Although
the interactions of these agents were not found in our study, as the
agents were not widely used at the time of data collection and few
evidences showed the potential interactions between different
biologic agents, awareness should be taken when prescribing these
medications.29
Study limitations
The ﬁndings of our study should be interpreted with caution
because of the limitations below: ﬁrst, our study focused only on
potential DIs in outpatient prescriptions, and we did not attempt to
survey the real occurrence of DIs and corresponding ADEs resulting
from DIs. Second, we did not evaluate some important factors that
would contribute to ADEs with DIs. Those factors include patient
age, genetics, comorbidities, major organ function status, and drug
compliance.30 Third, we assessed only prescriptions on a single
sheet, but not interactions with other medications prescribed on
the other sheets of the same patient or the same periods of time.
Furthermore, all generic pharmaceutical ingredients were taken as
one regardless of its formulations, so the potential DIs might be
over- or underestimated. Because of those weaknesses, we suggest
that the incidence of potential DIs may be underestimated in our
study population. Researchers who plan to do a future study on this
topic should consider addressing these study limitations.
Conclusion
By having analyzed a large-scale database, we can understand the
incidences, signiﬁcance levels, severity levels, and drug types of
potential DIs in dermatologic outpatient prescriptions. Although
the DI incidence rates are low, we would like to remind derma-
tologists of the potential DIs when prescribing medications. To
reduce potential DIs, we suggest introducing or integrating infor-
mation technology into the computerized physician order entry
system into the daily practice.
Y.-J. Chang et al. / Dermatologica Sinica 29 (2011) 81e85 85Acknowledgments
We would like to thank Professor Winston W. Shen who gave
English editing comments on part of this manuscript. This article
was presented in part at the 30th and 31st Annual Meetings of
Taiwanese Dermatological Association in 2004 and 2005. This
project was supported by research grant FEMH-93C-010 from the
Far Eastern Memorial Hospital, Taiwan.References
1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in
hospitalized patients: a meta-analysis of prospective studies. JAMA
1998;279:1200e5.
2. Kohn LT, Corrigan J, Donaldson MS. To err is human: building a safer health
system. Washington, DC: National Academy Press; 2000.
3. Great Britain. Dept. of Health. An organisation with a memory: report of an expert
group on learning from adverse events in the NHS. London: Stationery Ofﬁce;
2000.
4. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and
potential adverse drug events. Implications for prevention. ADE Prevention
Study Group. JAMA 1995;274:29e34.
5. Guedon-Moreau L, Ducrocq D, Duc MF, et al. Absolute contraindications in
relation to potential drug interactions in outpatient prescriptions: analysis of
the ﬁrst ﬁve million prescriptions in 1999. Eur J Clin Pharmacol
2003;59:689e95.
6. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in
hospitalized patients. Excess length of stay, extra costs, and attributable
mortality. JAMA 1997;277:301e6.
7. Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospi-
talized patients. Results of the Harvard Medical Practice Study II. N Engl J Med
1991;324:377e84.
8. Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse events and negli-
gence in hospitalized patients. Results of the Harvard Medical Practice Study I.
N Engl J Med 1991;324:370e6.
9. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care.
N Engl J Med 2003;348:1556e64.
10. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolﬁni C, Bonati M.
Incidence of adverse drug reactions in paediatric in/out-patients: a systematic
review and meta-analysis of prospective studies. Br J Clin Pharmacol
2001;52:77e83.11. Glassman PA, Simon B, Belperio P, Lanto A. Improving recognition of drug
interactions: beneﬁts and barriers to using automated drug alerts. Med Care
2002;40:1161e71.
12. Litt JZ. Litt’s drug eruption reference manual including drug interactions. London
and New York: Taylor & Francis; 2004.
13. Roujeau JC, Allanore L, Liss Y, Mockenhaupt M. Severe Cutaneous Adverse
Reactions to Drugs (SCAR): deﬁnitions, diagnostic criteria, genetic predisposi-
tion. Dermatol Sinica 2009;27:203e9.
14. Andersen WK, Feingold DS. Adverse drug interactions clinically important for
the dermatologist. Arch Dermatol 1995;131:468e73.
15. Barranco VP. Clinically signiﬁcant drug interactions in dermatology. J Am Acad
Dermatol 1998;38:599e612.
16. Barranco VP. Update on clinically signiﬁcant drug interactions in dermatology.
J Am Acad Dermatol 2004;51:E4.
17. Barranco VP. Update on clinically signiﬁcant drug interactions in dermatology.
J Am Acad Dermatol 2006;54:676e84.
18. Program overview of national health insurance. Available from: http://www.nhi.
gov.tw/English/webdata/webdata.aspx?menu¼11&;menu_id¼590&webdata_
id¼3189&WD_ID¼590; Nov. 17, 2009. Accessed April 29, 2011.
19. Huang YL, Chen YJ, Lin MW, et al. Malignancies associated with dermato-
myositis and polymyositis in Taiwan: a nationwide population-based study. Br
J Dermatol 2009;161:854e60.
20. Lee DD, Huang CK, Ko PC, Chang YT, Sun WZ, Oyang YJ. Association of primary
cutaneous amyloidosis with atopic dermatitis: a nationwide population-based
study in Taiwan. Br J Dermatol 2011;164:148e53.
21. Tatro DS. Drug interaction facts 2001. St Louis, MO: Facts & Comparisons; 2001.
22. Tatro DS. Signiﬁcance rating, Drug interaction facts 2001. St Louis, MO: Facts &
Comparisons; 2001. p. xivexv.
23. Yagiela JA. Adverse drug interactions in dental practice: interactions associated
with vasoconstrictors: part V of a series. J Am Dental Assoc 1999;130:701e9.
24. Tatro DS. Corticosteroid and antacids, Drug interaction facts 2001. St Louis, MO:
Facts & Comparisons; 2001. p. 367.
25. Del Rosso JQ. Oral antibiotic drug interactions of clinical signiﬁcance to
dermatologists. Dermatol Clin 2009;27:91e4.
26. Davidson KW, Kahn A, Price RD. Reduction of adverse drug reactions by
computerized drug interaction screening. J Fam Pract 1987;25:371e5.
27. Murff HJ, Patel VL, Hripcsak G, Bates DW. Detecting adverse events for patient
safety research: a review of current methodologies. J Biomed Inform
2003;36:131e43.
28. Bates DW, Gawande AA. Improving safety with information technology. N Engl
J Med 2003;348:2526e34.
29. Callen JP. Complications and adverse reactions in the use of newer biologic
agents. Semin Cutan Med Surg 2007;26:6e14.
30. Tey HL, Tian EL, Tan AW. Drug interactions in dermatological practice. Clin Exp
Dermatol 2008;33:541e50.
